Another state official has jumped on the Amphastar-bashing bandwagon. At a news conference Wednesday, Vermont Gov. Peter Shumlin called out Amphastar for boosting the price of its opioid antidote naloxone 62% over the course of a month.
Police and public safety departments around the country have been stocking up on naloxone from Amphastar Pharmaceuticals and other makers as a way to fight heroin and painkiller overdoses. But with prices for the drug doubling in the last year, some are accusing the small California company of overpricing the overdose drug and are asking for some of their money back.
Momenta Pharmaceuticals really wants the U.S. Supreme Court to weigh its argument against Amphastar's rival version of generic Lovenox. But Amphastar is equally eager to keep the Supreme Court out of the case.
Momenta Pharmaceuticals ($MNTA) has lost its exclusive hold on the generic Lovenox market--at least temporarily. Amphastar, which has been developing its own version of the Sanofi ($SNY)
It's official: Sanofi ($SNY) has discontinued its authorized generic version of the Lovenox blood thinner. Apparently, the company thinks it can make more money selling the branded med only, since
It looks as if Momenta Pharmaceuticals ($MNTA) will keep its share of the market for copycat Lovenox. The U.S.-based drugmaker and its partner Sandoz won an injunction against two potential rivals
Amphastar Pharmaceuticals finally has the FDA's blessing. After a protracted battle marked by lawsuits against the agency and conflicts of interest allegations, the company got U.S. regulatory
The FDA's approval of copycat Lovenox has now spawned two lawsuits. The latest comes from Amphastar Pharmacteuticals, one generics maker that didn't win the agency nod. It is accusing the agency of
Amphastar is taking its battle with Momenta Pharmaeuticals to federal court, albeit in a roundabout way. The company has jumped into a mass tort case against Baxter and Scientific Protein